Heinrich Rder - Biodesix Founder CTO
| BDSX Stock | USD 1.33 0.05 3.91% |
Insider
Heinrich Rder is Founder CTO of Biodesix
| Address | 919 West Dillon Road, Louisville, CO, United States, 80027 |
| Phone | 303 417 0500 |
| Web | https://www.biodesix.com |
Biodesix Management Efficiency
The company has return on total asset (ROA) of (0.2279) % which means that it has lost $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3182) %, meaning that it created substantial loss on money invested by shareholders. Biodesix's management efficiency ratios could be used to measure how well Biodesix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.72 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Biodesix's Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to rise to about 7.2 M in 2024, whereas Total Assets are likely to drop slightly above 86.1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Patricia CPA | Enzo Biochem | 46 | |
| Shaokun Chuai | Burning Rock Biotech | 45 | |
| MD Frcp | Aclaris Therapeutics | 63 | |
| Ian Anderson | Aclaris Therapeutics | N/A | |
| Bradley Radoff | Enzo Biochem | 47 | |
| MingChou Lee | Exagen Inc | N/A | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| Zvi David | DarioHealth Corp | 63 | |
| Paul Kearney | Sera Prognostics | 56 | |
| MD FACR | Exagen Inc | N/A | |
| Steven Graves | Sera Prognostics | N/A | |
| Zhihong Zhang | Burning Rock Biotech | 48 | |
| Claire Sears | Neuronetics | N/A | |
| Dieter MD | Enzo Biochem | 61 | |
| Rebecca Fischer | Enzo Biochem | 52 | |
| Peter Clemens | Enzo Biochem | N/A | |
| James Loerop | Aclaris Therapeutics | 59 | |
| Dov Oppenheim | DarioHealth Corp | N/A | |
| John Boniface | Sera Prognostics | 62 | |
| Joseph Monahan | Aclaris Therapeutics | 67 | |
Management Performance
| Return On Equity | -3.32 | ||||
| Return On Asset | -0.23 |
Biodesix Leadership Team
Elected by the shareholders, the Biodesix's board of directors comprises two types of representatives: Biodesix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biodesix. The board's role is to monitor Biodesix's management team and ensure that shareholders' interests are well served. Biodesix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biodesix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James MD, CoChief Officer | ||
| Robin Cowie, Secretary CFO | ||
| Matt Stauffer, VP Sales | ||
| Christopher Vazquez, Controller VP | ||
| Dr III, Chief Officer | ||
| Ryan Siurek, Chief Officer | ||
| Heinrich Rder, Founder CTO | ||
| Paul Beresford, Chief Officer | ||
| Steven Springmeyer, CoChief Officer | ||
| Robert Cawthorn, Founder Emeritus | ||
| Jeffrey Bojar, VP Affairs | ||
| Kieran OKane, Chief Officer | ||
| Gary Pestano, Chief Officer | ||
| Mark DeBlock, Vice Sales | ||
| Scott Hutton, CEO President | ||
| Robbie Lunt, Senior Marketing | ||
| Bobbi Coffin, Chief Officer | ||
| Jessica Olbricht, Senior Resources |
Biodesix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biodesix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.32 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 216.75 M | ||||
| Shares Outstanding | 145.47 M | ||||
| Shares Owned By Insiders | 47.11 % | ||||
| Shares Owned By Institutions | 38.63 % | ||||
| Number Of Shares Shorted | 415.74 K | ||||
| Price To Book | 6.68 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodesix Stock Analysis
When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.